Gynecologic Oncology

Article	Citations
Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990–2019	155
Outcomes of enhanced recovery after surgery (ERAS) in gynecologic oncology – A systematic review and meta-analysis.	106
Stromal POSTN induced by TGF-β1 facilitates the migration and invasion of ovarian cancer	83
Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes	79
Clinical assays for assessment of homologous recombination DNA repair deficiency	71
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer	71
Uterine serous carcinoma	70
Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study	69
Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity	69
Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes	66
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer	65
Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment	64
Validation of American College of Radiology Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US): Analysis on 1054 adnexal masses	60
Exosomal microRNAs and exosomal long non-coding RNAs in gynecologic cancers	60
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial	59
Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations	57
Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer	56
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer	54
Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial	54
Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis	51
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study	49
Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study	48
Lymphovascular space invasion in endometrial carcinoma: A prognostic factor independent from molecular signature	45
Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends	45
Homologous recombination deficiency real-time clinical assays, ready or not?	44

Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 update	44
Natural language processing with machine learning to predict outcomes after ovarian cancer surgery	42
Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma	42
The current landscape of molecular profiling in the treatment of epithelial ovarian cancer	42
Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer	42
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review	41
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian can	41
Ten-year outcomes following laparoscopic and open abdominal radical hysterectomy for “low-risk” early-stage cervical cancer: A propensity-score based analysis	41
GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function	39
Non-coding RNAs related to angiogenesis in gynecological cancer	39
Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer	38
Gynecologic oncology care during the COVID-19 pandemic at three affiliated New York City hospitals	37
The feature of cervical microbiota associated with the progression of cervical cancer among reproductive females	36
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)	36
High-risk HPV-positive and -negative high-grade cervical dysplasia: Analysis of 5-year outcomes	36
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer	36
Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer	36
The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration	35
Naples prognostic score is an independent prognostic factor in patients with operable endometrial cancer: Results from a retrospective cohort study	35
Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer	34
Sentinel node mapping vs. sentinel node mapping plus back-up lymphadenectomy in high-risk endometrial cancer patients: Results from a multi-institutional study	34
Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol	34
A systematic review on the use of artificial intelligence in gynecologic imaging – Background, state of the art, and future directions	34
Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer	34
Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?	34
Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy	33
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial	33
Global distribution, risk factors, and recent trends for cervical cancer: A worldwide country-level analysis	33
The role of semiquantitative evaluation of lympho-vascular space invasion in early stage cervical cancer patients	32
Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases	32
A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study	32
Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial	32
Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An international multi-institutional study	31
Preoperative frailty assessment in patients undergoing gynecologic oncology surgery: A systematic review	30
[18F]FDG-PET or PET/CT in the evaluation of pelvic and para-aortic lymph nodes in patients with locally advanced cervical cancer: A systematic review of the literature	30
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis	30
The ASTRO clinical practice guidelines in cervical cancer: Optimizing radiation therapy for improved outcomes	29
Racial disparities in high-risk uterine cancer histologic subtypes: A United States Cancer Statistics study	29
Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients	29
Updates on conservative management of endometrial cancer in patients younger than 45 years	29
Management and outcomes of primary vaginal Cancer	29
Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?	29
Oncologic results of fertility sparing surgery of cervical cancer: An updated systematic review	29
Racial and ethnic disparities in palliative care utilization among gynecological cancer patients	29
Neuroendocrine tumors of the gynecologic tract update	29
Modified fragility index and surgical complexity score are able to predict postoperative morbidity and mortality after cytoreductive surgery for advanced ovarian cancer	28
Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, plac	28
Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer	28
Near-infrared fluorescence imaging compared to standard sentinel lymph node detection with blue dye in patients with vulvar cancer – a randomized controlled trial	28
Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation	28

Clinical impact of low-volume lymph node metastases in early-stage cervical cancer: A comprehensive meta-analysis	28
A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanc	28
Adapting and avoiding coping strategies for women with ovarian cancer during the COVID-19 pandemic	28
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab	28
Clear cell carcinoma of the endometrium	28
The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes	28
Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database	28
Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification	27
Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis	27
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer	27
Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification	27
Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer	27
Prospective analysis of circulating metabolites and endometrial cancer risk	27
Tumor-infiltrating lymphocytes predict survival outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy	27
Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)	27
Tumor-infiltrating lymphocytes and POLE mutation in endometrial carcinoma	27
Mitigation and management strategies for ocular events associated with tisotumab vedotin	26
Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials	26
Feasibility, acceptability and effects of multimodal pelvic floor physical therapy for gynecological cancer survivors suffering from painful sexual intercourse: A multicenter prospective interventiona	26
Racial disparities in survival among women with endometrial cancer in an equal access system	26
Crowdsourcing to measure financial toxicity in gynecologic oncology	26
Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer: A systematic review	26
Clinical significance of homologous recombination deficiency score testing in endometrial Cancer	25
Differences in cervical cancer screening and follow-up for black and white women in the United States	25
Impact of Obesity on Sentinel Lymph Node Mapping in Patients with apparent Early-Stage Endometrial Cancer: The ObeLyX study	25
Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis	25
The impact of marital status on stage at diagnosis and survival of female patients with breast and gynecologic cancers: A meta-analysis	25
Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples	25
The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis	25
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study	25
A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer	25
Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines	24
Angiogenesis in endometrial carcinoma: Therapies and biomarkers, current options, and future perspectives	24
Clinical needs for transgender men in the gynecologic oncology setting	24
Using machine learning to create prognostic systems for endometrial cancer	24
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer	24
Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States	24
Decreasing utilization of minimally invasive hysterectomy for cervical cancer in the United States	24
Is routine omentectomy of grossly normal omentum helpful in surgery for ovarian cancer? A look at the tumor microenvironment and its clinical implications	24
Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies	24
Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma	24
The next generation sequencing of cancer-related genes in small cell neuroendocrine carcinoma of the cervix	24
Clear cell endometrial carcinomas with mismatch repair deficiency have a favorable prognosis: A systematic review and meta-analysis	24
Age-related distribution of uncommon HPV genotypes in cervical intraepithelial neoplasia grade 3	23
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer	23
Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study	23
Stereotactic body radiation therapy for oligometastatic gynecologic malignancies: A systematic review	23
Diagnostic value of indocyanine green fluorescence guided sentinel lymph node biopsy in vulvar cancer: A systematic review	23
Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer	23
Neoadjuvant chemotherapy followed by fertility sparing surgery in cervical cancers size 2–4 cm; emerging data and future perspectives	23
Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer	23
Adherence to treatment guidelines as a major determinant of survival disparities between black and white patients with ovarian cancer	23
Effect of frailty on postoperative readmissions and cost of care for ovarian cancer	23
ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer	23
Rural disparities in surgical care from gynecologic oncologists among Midwestern ovarian cancer patients	23
Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer: A post-hoc analysis of SENTICOL I and SENTICOL II cohorts	23
Laparo-assisted vaginal radical hysterectomy as a safe option for Minimal Invasive Surgery in early stage cervical cancer: A systematic review and meta-analysis	23
A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer	23
DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: Real-world evidence in Taiwan	22
Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape.	22
Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort	22
Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy	22
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZ	22
Maintaining surgical care delivery during the COVID-19 pandemic: A comparative cohort study at a tertiary gynecological cancer centre	22
Frailty Index for prediction of surgical outcome in ovarian cancer: Results of a prospective study	22
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial	22
Recurrence and survival after laparoscopy versus laparotomy without lymphadenectomy in early-stage endometrial cancer: Long-term outcomes of a randomised trial	22
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial	22
Prognostic value of systemic hemato-immunological indices in uterine cervical cancer: A systemic review, meta-analysis, and meta-regression of observational studies	22
Using rADioMIcs and machine learning with ultrasonography for the differential diagnosis of myometRiAL tumors (the ADMIRAL pilot study). Radiomics and differential diagnosis of myometrial tumors	22
MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer	21
Cost-effectiveness analysis comparing “PARP inhibitors-for-all” to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer	21
Patterns of recurrence and survival in vulvar cancer: A nationwide population-based study	21
A population-based study of causes of death after endometrial cancer according to major risk factors	21
Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer	21
PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer	21
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer	21
Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer	21
Visceral obesity and muscle mass determined by CT scan and surgical outcome in patients with advanced ovarian cancer. A retrospective cohort study	21
Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification	21

Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer	21
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study	21
Direct oral anticoagulant use in gynecologic oncology: A Society of Gynecologic Oncology Clinical Practice Statement	20
Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013–2019	20
Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy	20
Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: Multicenter, randomized controlled trial	20
Perceived patient-centered communication, quality of life, and symptom burden in individuals with ovarian cancer	20
Virtual visits among gynecologic oncology patients during the COVID-19 pandemic are accessible across the social vulnerability spectrum	19
Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study (LBA 4)	19
Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis	19
Sentinel lymph node mapping in early-stage cervical cancer – A national prospective multicenter study (SENTIREC trial)	19
Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancer	19
Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II	19
Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer	19
Impact of the COVID-19-pandemic on patients with gynecological malignancies undergoing surgery: A Dutch population-based study using data from the ‘Dutch Gynecological Oncology Audit’	19
TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review	19
Cervical conization before primary radical hysterectomy has a protective effect on disease recurrence in early cervical cancer: A two-center matched cohort study according to surgical approach	18
The impact of a Facebook campaign among mothers on HPV vaccine uptake among their daughters: A randomized field study	18
The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis	18
An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial	18
Utilization and perioperative outcome of minimally invasive pelvic exenteration in gynecologic malignancies: A national study in the United States	18
Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations	18
Pembrolizumab treatment of advanced cervical cancer: updated results from the phase II KEYNOTE-158 study	18
Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer	18
Upstaging by para-aortic lymph node dissection in patients with locally advanced cervical cancer: A systematic review and meta-analysis	18
Post-recurrence survival in patients with cervical cancer	18
Pre-treatment inflammatory parameters predict survival from endometrial cancer: A prospective database analysis	18
The effect of guideline-concordant care in mitigating insurance status disparities in cervical cancer	18
Diet and gut microbiome interactions in gynecologic cancer	18
Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial	18
Rural residence is related to shorter survival in epithelial ovarian cancer patients	18
The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma	17
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma	17
Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States	17
Spotlight on the role of human papillomavirus vaccines	17
Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer	17
Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis	17
Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6)	17
Molecular profiles of endometrial cancer tumors among Black patients	17
Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers	17
Clinicopathological characteristics and prognosis of cervical cancer with different histological types: A population-based cohort study	17
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients	17
The MEMORY Study: MulticentEr study of Minimally invasive surgery versus Open Radical hYsterectomy in the management of early-stage cervical cancer: Survival outcomes	17
The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis	17
Talc, body powder, and ovarian cancer: A summary of the epidemiologic evidence	17
Final overall survival results from SOLO3: Phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1 - and/or BRCA2-mutated pla	17
Resection of the upper paracervical lymphovascular tissue should be an integral part of a pelvic sentinel lymph node algorithm in early stage cervical cancer	17
Imiquimod for vaginal intraepithelial neoplasia 2–3: A systematic review and meta-analysis	17
Ambient air pollution and ovarian cancer survival in California	17
Preoperative controlling nutritional status (CONUT) score is a prognostic factor for early-stage cervical cancer patients with high-risk factors	17
Sentinel lymph node biopsy in patients with endometrial cancer and an indocyanine green or iodinated contrast reaction - A proposed management algorithm	17
Survival outcomes in patients with cervical cancer treated with open versus robotic radical hysterectomy: Our surgical pathology interrogation	16
Sentinel lymph node mapping in patients with endometrial hyperplasia: A practice to preserve or abandon?	16
Predictor factors for conservative management of cervical intraepithelial neoplasia grade 2: Cytology and HPV genotyping	16
The five-factor modified frailty index predicts adverse postoperative and chemotherapy outcomes in gynecologic oncology	16
Water only fasting and its effect on chemotherapy administration in gynecologic malignancies	16
Testing for lynch syndrome in people with endometrial cancer using immunohistochemistry and microsatellite instability-based testing strategies – A systematic review of test accuracy	16
Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy	16
Racial and ethnic differences in type II endometrial cancer mortality outcomes: The contribution of sociodemographic, clinicopathologic, and treatment factors	16
Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers	16
Risk factors analysis of persistence, progression and recurrence in vaginal intraepithelial neoplasia	16
Should the risk for uterine cancer influence decision making for prophylactic hysterectomy in BRCA1/2 mutated patients- a systematic review and meta-analysis	16
Circulating cell-free tumor human papillomavirus DNA is a promising biomarker in cervical cancer	16
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer	16
Management of pregnancy after radical trachelectomy	16
Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study	16
Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer	16
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI – GINECO study	16
A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer	16
Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma	16
Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO)	15
Long-term oncological outcomes and recurrence patterns in early-stage cervical cancer treated with minimally invasive versus abdominal radical hysterectomy: The Norwegian Radium Hospital experience	15
Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage	15
An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study	15
HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status	15
Sexual harassment and gender discrimination in gynecologic oncology	15
Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis	15
REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer	15
Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis	15
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymeras	15
Is sentinel lymph node assessment useful in patients with a preoperative diagnosis of endometrial intraepithelial neoplasia?	15
Why not de-intensification for uterine cervical cancer?	15
Prognostic value of the 2018 FIGO staging system for cervical cancer	15
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary perit	15
Genetically predicted circulating protein biomarkers and ovarian cancer risk	15
Lymph node assessment at the time of hysterectomy has limited clinical utility for patients with pre-cancerous endometrial lesions	15
Cost-effectiveness of apixaban for prevention of venous thromboembolic events in patients after gynecologic cancer surgery	15
State of the Science: The role of HIPEC in the treatment of ovarian cancer	15
Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility	15
Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer	15
Disparities in cervical cancer survival in the United States by race and stage at diagnosis: An analysis of 138,883 women diagnosed between 2001 and 2014 (CONCORD-3)	15
Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial	15
Robot-assisted versus laparoscopic minimally invasive surgery for the treatment of stage I endometrial cancer	15
Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer	15
Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study	15